Drugs / LTP001
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06649110 | Oct 2024 → Nov 2028 expected | pulmonary arterial hypertension | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 23 trials · 1 missed | ||||||
| Phase 2 | NCT05764265 | Mar 2023 → Apr 2024 | pulmonary arterial hypertension | Novartis Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT05497284 | Nov 2022 → Aug 2024 | idiopathic pulmonary fibrosis | Novartis Pharmaceuticals | Terminated | Missed primary Stop: Business |
| Phase 2 | NCT05135000 | Jun 2022 → Mar 2024 | pulmonary arterial hypertension | Novartis Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LTP001 | “A study to learn about the treatment LTP001 in healthy participants (Part A) and in participants with PAH (Part B)” NCT06649110 ↗ |
| Route | Oral | “administered orally” NCT05135000 ↗ |